Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

NCT ID: NCT01900015

Last Updated: 2017-07-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-03
• Study Completion Date: 2017-01-17

Brief Summary

Primary Objective:

To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among HIV/HCV-coinfected patient.

Secondary Trial Objective:

1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in the grade of HS between patients continuing with EFV plus two nucleoside analogs and those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside analogs.

2. To evaluate the proportion of patients who maintain viral control (HIV RNA < 50 copies/mL) after switching.

Design:

Open-label, randomized clinical trial to evaluate safety (phase IV)

Condition:

HIV and HCV coinfection.

Intervention:

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Detailed Description

Primary Objective:

To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as measured by the controlled attenuation parameter (CAP) among HIV/HCV-coinfected patient.

Secondary Trial Objective:

1. To compare the proportion of HIV/HCV-coinfected patients with one category decrease in the grade of HS between patients continuing with EFV plus two nucleoside analogs and those switching from EFV plus two nucleoside analogs to RAL plus two nucleoside analogs.

2. To evaluate the proportion of patients who maintain viral control (HIV RNA < 50 copies/mL) after switching.

Design:

Open-label, randomized clinical trial to evaluate safety (phase IV)

Condition:

HIV and HCV coinfection.

Intervention:

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Study population and sample size HIV-infected patients with concomitant coinfection by HCV, as shown by detectable plasma HCV RNA, not candidates for therapy against HCV infection during the 48 week period of the Number of patients to recruit: 96, 48 patients per treatment group should be recruited.

Conditions

HCV Coinfection; HIV Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Raltegravir

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Group Type: ACTIVE_COMPARATOR

Raltegravir

Intervention Type: DRUG

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Efavirenz

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Group Type: ACTIVE_COMPARATOR

Efavirenz

Intervention Type: DRUG

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Interventions

Raltegravir

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Intervention Type: DRUG

Efavirenz

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Intervention Type: DRUG

Other Intervention Names

Issentres; Sustiva

Eligibility Criteria

Inclusion Criteria

1. Each subject must be willing and able to provide written informed consent for the trial.

2. Each subject must be ≥ 18 years of age.

3. Each subject must be male or non-pregnant, non-breastfeeding female

4. Each subject must have diagnosis of HIV infection.

5. Each subject must have concomitant coinfection by HCV as shown by detectable plasma HCV RNA.

6. Each subject must have stable treatment with EFV plus two nucleoside analogs for ≥24 weeks.

7. Each subject must have at least 2 documented plasma HIV RNA <50 copies/ml during the last 24 weeks, as observed in, at least, two clinical visits.

8. Each subject must have HS involving more than 10% of hepatocytes, as determined by a CAP measurement ≥238 dB/m.

9. Each sexually active female subject of child-bearing potential must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 3 months after stopping the medication.Medically accepted methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, inert or copper-containing IUD, hormone releasing IUD, systemic hormonal contraceptive, and surgical sterilization (eg,hysterectomy or tubal ligation).Postmenopausal women are not required to use contraception.Postmenopausal is defined as at least 12 consecutive months without a spontaneous menstrual period.

10. Each sexually active male subject with a female partner(s) of child-bearing potential must also provide written informed consent to provide information regarding any pregnancy.

11. Average daily alcohol intake lower than 50 g for men and 40 g for women.

Exclusion Criteria

1. The subject has an allergy/sensitivity to investigational product or its/their excipients.

2. The female subject is nursing.

3. The female subject is pregnant or intending to become pregnant.

4. History of ARV failure or documented resistance.

5. Baseline resistance to EFV or to any of the nucleoside analogues inhibitors in the regimen.

6. The subject has any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.

7. The subject has active AIDS-defining event (CDC-C) within 24 weeks before screening.

8. The subject is candidate for therapy against HCV infection during the 48 week trial period in the opinion of the investigator.

9. The subject has a history of malignant neoplasia.

10. Active illicit drug use or any other condition that may compromise the study drug adherence in the opinion of the investigators.

11. The subject has used any investigational drugs within 30 days of Baseline.

12. A subject who has participated in any other clinical trial within 30 days,inclusive, of signing the informed consent form of the current trial.

13. The subject or a family member is among the personnel of the investigational or SPONSOR staff directly involved with this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Juan Macías

OTHER_GOV

Sponsor Role: lead

Responsible Party

Juan Macías

PhD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Juan Macías, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Infectious Diseases and Microbiology Unit. Hospital Universitario de Valme. Servicio Andaluz de Salud

Locations

Hospital La Línea

La Línea de la Concepción, Cádiz, Spain

H.U. Valme

Seville, Seville, Spain

Hospital Universitario Reina Sofía

Córdoba, , Spain

Hospital Infanta Elena

Huelva, , Spain

Complejo Hospitalario de Jaen

Jaén, , Spain

Hospital Universitario 12 de Octubre

Madrid, , Spain

Hospital Universitario La Paz

Madrid, , Spain

Hospital Regional Universitario Carlos Haya

Málaga, , Spain

Hospital Universitario Virgen de la Victoria

Málaga, , Spain

Hospital Universitario Virgen del Rocío

Seville, , Spain

Countries

Spain

References

Macias J, Mancebo M, Merino D, Tellez F, Montes-Ramirez ML, Pulido F, Rivero-Juarez A, Raffo M, Perez-Perez M, Merchante N, Cotarelo M, Pineda JA; Spanish AIDS Research Network-HEP09 Study Group. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2017 Sep 15;65(6):1012-1019. doi: 10.1093/cid/cix467.

Reference Type: DERIVED

PMID: 28903510 (View on PubMed)

Related Links

http://www.croiconference.org/sessions/changes-liver-steatosis-after-switching-efavirenz-raltegravir-steral-study-0

Abstract presented at CROI 2017. Poster available to download

http://www.croiwebcasts.org/p/2017croi/croi33405

CROI webcast. THEMED DISCUSSION: OBESITY AND FATTY LIVER DISEASE

Other Identifiers

STERAL/50410

Identifier Type: -

Identifier Source: org_study_id